PER 2.47% 8.3¢ percheron therapeutics limited

It's not easy to predict how the market will react to the...

  1. 374 Posts.
    It's not easy to predict how the market will react to the results.
    Key points will be reduction %, tolerance, efficacy, safety.
    The only way to assess this is to compare it to Somavert.
    Somavert earns pzifer 200mil a year, the product is expensive, a daily injected treatment, and has well documented side effects.
    If ATL achieves similar % reduction but is safer and well tolerated, I'd expect ATL to become a the top shelf product as it only requires a weekly self administered injection and is predicted to be half the cost.
    Expect positive data to fetch us a 50+ mil market cap, that's very fair. I also expect that if partnering hasn't happened within a very short period of the announcement, I believe a take over will undoubtably happen.
    It all comes down to a magical % of IGF reductions. We were close prelim. Fingers crossed.
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.3¢
Change
0.002(2.47%)
Mkt cap ! $74.82M
Open High Low Value Volume
9.0¢ 9.0¢ 8.2¢ $9.57K 112.6K

Buyers (Bids)

No. Vol. Price($)
2 124862 8.1¢
 

Sellers (Offers)

Price($) Vol. No.
8.9¢ 11000 1
View Market Depth
Last trade - 15.56pm 29/03/2024 (20 minute delay) ?
Last
8.2¢
  Change
0.002 ( 0.86 %)
Open High Low Volume
8.2¢ 8.3¢ 8.2¢ 31700
Last updated 15.55pm 29/03/2024 ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.